Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Grants and contracts	$ 236,519	$ 0	$ 236,519	$ 0
Cost of Revenue:
Cost of goods sold	115,927	0	115,927	0
Gross Profit	120,592	0	120,592	0
Operating expenses:
Research and development	3,434,977	4,383,325	6,274,936	4,509,890
Sales and marketing expense	23,242	0	26,037	0
General and administrative	6,306,323	1,787,333	14,981,086	2,284,577
Total operating expenses	9,764,542	6,170,658	21,282,059	6,794,467
Loss from operations	(9,643,950)	(6,170,658)	(21,161,467)	(6,794,467)
Other income (expense):
Interest and other income (expense)	(3,089,301)	491,817	(3,463,572)	(1,069,403)
Total other income (expense)	(3,089,301)	491,817	(3,463,572)	(1,069,403)
Income from discontinued operations, net of income taxes	(1)	0	(1)	0
Net loss	(12,733,250)	(5,678,841)	(24,625,038)	(7,863,870)
Net loss attributable to noncontrolling interests	13,419	0	13,419	0
Net loss attributable to Statera Biopharma, Inc.	$ (12,719,831)	$ (5,678,841)	$ (24,611,619)	$ (7,863,870)
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share)	$ (0.47)	$ (1.84)	$ (0.86)	$ (1.13)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in shares)	27,036,583	3,081,294	28,671,422	6,957,095